Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa by Kuhle, Jens et al.
Clin Chem Lab Med 2016; 54(10): 1655–1661
aKaj Blennow and Henrik Zetterberg contributed equally to this work.
*Corresponding author: Jens Kuhle, MD, PhD, Neurology, 
Departments of Medicine, Biomedicine and Clinical Research, 
University Hospital Basel, Basel, Switzerland,  
Phone: +41 (0)613287191; Fax: +41 (0)612654100,  
E-mail: jens.kuhle@usb.ch
Christian Barro, Tobias Derfuss and Raija Lindberg: Neurology, 
Departments of Medicine, Biomedicine and Clinical Research, 
University Hospital Basel, Basel, Switzerland
Ulf Andreasson, Åsa Sandelius, Victor Liman and Kaj Blennow: 
Institute of Neuroscience and Physiology, Department of Psychiatry 
and Neurochemistry, The Sahlgrenska Academy, University of 
Gothenburg, Mölndal, Sweden
Niklas Norgren: UmanDiagnostics, Umeå, Sweden
Henrik Zetterberg: Institute of Neuroscience and Physiology, 
Department of Psychiatry and Neurochemistry, The Sahlgrenska 
Academy, University of Gothenburg, Mölndal, Sweden; and 
UCL Insitute of Neurology, Department of Psychiatry and 
Neurochemistry, Queen Square, London, UK
Jens Kuhle*, Christian Barro, Ulf Andreasson, Tobias Derfuss, Raija Lindberg, Åsa Sandelius, 
Victor Liman, Niklas Norgren, Kaj Blennowa and Henrik Zetterberga
Comparison of three analytical platforms for 
quantification of the neurofilament light chain in 
blood samples: ELISA, electrochemiluminescence 
immunoassay and Simoa
DOI 10.1515/cclm-2015-1195
Received December 2, 2015; accepted March 7, 2016; previously 
 published online April 12, 2016
Abstract
Background: Neuronal damage is the morphological 
substrate of persisting neurological disability. Neurofila-
ments (Nf) are specific cytoskeletal proteins of neurons 
and their quantification has shown encouraging results 
as a biomarker for axonal injury.
Methods: We aimed at comparing a widely used con-
ventional ELISA for Nf light chain (NfL) with an electro-
chemiluminescence-based method (ECL assay) and a 
newly developed single-molecule array (Simoa) method 
in clinically relevant cerebrospinal fluid (CSF) and serum 
samples.
Results: Analytical sensitivity was 0.62 pg/mL for Simoa, 
15.6  pg/mL for the ECL assay, and 78.0  pg/mL for the 
ELISA. Correlations between paired CSF and serum 
samples were strongest for Simoa (r = 0.88, p < 0.001) and 
the ECL assay (r = 0.78, p < 0.001) and weaker for ELISA 
measurements (r = 0.38, p = 0.030). CSF NfL measurements 
between the platforms were highly correlated (r = 1.0, 
p < 0.001). Serum NfL levels were highly related between 
ECL assay and Simoa (r = 0.86, p < 0.001), and this was less 
visible between ELISA-ECL assay (r = 0.41, p = 0.018) and 
ELISA-Simoa (r = 0.43, p = 0.013). Multiple sclerosis (MS) 
patients had significantly higher serum NfL levels than 
controls when measured with Simoa (p = 0.001) but not 
with the other platforms.
Conclusions: We found Simoa to be more sensitive than 
ELISA or the ECL assay. Our results support the feasibility 
of quantifying NfL in serum; the results correlate with the 
more-established CSF NfL test. The highly sensitive Simoa 
technology deserves further studies in larger patient 
cohorts to clarify whether serum NfL could be used in the 
future to measure disease severity and determine progno-
sis or response to treatment interventions in neurological 
diseases.
Keywords: immunoassay; neurodegeneration; neurofila-
ment light chain; serum.
Introduction
Highly sensitive methods for detecting soluble biomark-
ers for neuro-axonal damage are urgently needed in neu-
rodegenerative diseases. Neurofilaments (Nf) are highly 
specific major structural proteins of neurons consisting 
predominantly of three Nf subunits: Nf light (NfL), Nf 
medium (NfM), and Nf heavy (NfH) chains [1]. Disruption 
to the axonal membrane releases Nf into the interstitial 
fluid and eventually into the cerebrospinal fluid (CSF) 
and blood. Therefore, blood Nf levels could potentially 
be useful for both predicting and monitoring disease pro-
gression and for assessing the efficacy and/or toxicity of 
future neuroprotective treatment strategies. Numerous 
previous studies have demonstrated the presence of NfH 
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and NfL in CSF in a wide range of neurological diseases 
[2, 3]; however, obtaining longitudinal CSF samples is 
relatively invasive, precluding the broader clinical use 
of Nf. In contrast, serial blood samples can be readily 
collected; hence, reliable quantification of NfL in blood 
would be a major stride towards a biomarker of the course 
of neurodegeneration.
A commercially available ELISA (UmanDiagnostics 
NF-light assay ELISA) uses two highly specific, non-com-
peting monoclonal antibodies (mAB47:3 and mAB2:1) to 
quantify soluble NfL, but this assay is not recommended 
for blood measurements by the producer [4]. Electro-
chemiluminescence (ECL)-based assays are known to 
be highly sensitive, exhibit a broad dynamic range, and 
require small sample volume. We have recently devel-
oped an ECL immunoassay suitable for NfL measure-
ments in serum based on these mABs (ECL assay) [5]. 
Single-molecule array (Simoa) technology for digital 
immunoassays has the potential to improve sensitivity 
significantly further [6, 7]. The aim of this study was to 
compare the ELISA and ECL assay for NfL with a newly 
developed method based on Simoa technology using the 
same set of antibodies in clinically relevant and matched 
CSF and serum samples.
Materials and methods
CSF and serum samples
We selected pairs of CSF and serum samples based on previous 
serum NfL measurements with the ECL NfL assay: nine CSF and 
serum pairs with high (50–1800 pg/mL, high), eight with medium 
(5–15 pg/mL, medium), and seven with low ( < 4 pg/mL, low) serum 
NfL levels. In the group of patients with high NfL levels, four patients 
suffered from amyotrophic lateral sclerosis (ALS), three had Guillain-
Barré syndrome (GBS), and one patient each had a major stroke or 
acute disseminated encephalomyelitis (ADEM). The group of patients 
with medium NfL levels consisted of three patients with multiple sys-
tem atrophy (two Parkinsonian type and one cerebellar type), two 
patients each with non-infectious myelitis or stroke, and one patient 
with recurrent aseptic meningitis; the low NfL level group included 
four patients with tension-type headaches and one patient each 
with cryptogenic epilepsy, encephalopathy due to cannabis con-
sumption and a radiologically isolated syndrome (RIS). In addition, 
we included nine CSF and serum pairs from patients with multiple 
sclerosis (MS) that had not been measured before. Six patients had a 
relapsing remitting disease course [median expanded disability sta-
tus scale (EDSS): 6.5, interquartile range (IQR): 4.6–7.0, five patients 
with an acute relapse at sampling with onset of new symptoms 
within 30 days] and three were in the secondary progressive disease 
stage (median EDSS: 7.0, IQR: 6.5–7.5, three with acute relapse).
Samples were collected during routine diagnostic investigations 
as indicated by the treating physicians and collected and processed 
at room temperature within two hours (Neurology, University Hos-
pital Basel, Switzerland). Serum samples were spun at 2000 × g and 
CSF samples at 400 × g at room temperature for 10 min, aliquoted in 
polypropylene tubes and stored at –80 °C [8].
ELISA and ECL NfL assay
The NF-light assay ELISA was performed as described by the manu-
facturer. The ECL assay [5] was slightly modified: Coating was done 
with 0.05 M carbonate-bicarbonate buffer (pH 9.6) at 4 °C. Nonspe-
cific binding sites were blocked with 100 μL of TBS, containing 3% 
milk powder, per well for 1 h. We used 25 μL of TBS containing 1% 
milk powder, 0.1% Tween-20, and 600/300 μg/mL HeteroBlock® 
(Omega Biologicals, Bozeman, MT, USA) as sample diluent. Calibra-
tors were prepared in TBS containing 1% milk powder, 0.1% Tween-
20, and 300 μg/mL HeteroBlock®.
Simoa NfL assay
The Simoa NfL assay was established using the NF-light assay 
ELISA kit from UmanDiagnostics (UmanDiagnostics, Umeå, 
 Sweden), transferred onto the Simoa platform with a homebrew kit 
(Quanterix Corp, Boston, MA, USA), and detailed instructions can 
be found in the Simoa Homebrew Assay Development Guide (Quan-
terix). In short, paramagnetic carboxylated beads (Quanterix) were 
activated using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDAC) (Quanterix) by adding 5% (v/v) 10 mg/mL EDAC to a mag-
netic beads solution with 1.4 × 106 beads/μL. Following a 30-min 
incubation at room temperature (RT), the beads were washed using 
a magnetic separator, and an initial volume, i.e. EDAC+beads solu-
tion volumes in the previous step, of 0.3 mg/mL ice cold solution 
of the monoclonal capture antibody (mAB47:3, UmanDiagnostics) 
was added. After a 2-h incubation on a mixer (2000 rpm, Multi-Tube 
Vortexer, Allsheng, China) at RT, the beads were washed and an 
initial reaction volume of blocking solution was added. After three 
washes, the conjugated beads were suspended and stored at 4 °C 
pending analysis. The monoclonal detection antibody (1  mg/mL, 
mAB2:1, UmanDiagnostics) was biotinylated by adding 3% (v/v) 
3.4  mM EZ-Link™ NHS-PEG4-Biotin (Quanterix) followed by a 
30-min incubation at RT. Free biotin was removed using spin fil-
tration (Amicon® Ultra-2, 50 kDa, Sigma) and the biotinylated 
antibody was stored at 4 °C pending analysis. The assay was run 
on a Simoa HD-1 instrument (Quanterix) using a 2-step Assay Dilu-
tion 2.0 protocol using 25 μL conjugated beads, 75 μL diluent [PBS; 
0.1% Tween-20; 2% BSA; 10 mcg/mL TRU Block (Meridian Life Sci-
ence, Inc., Memphis, TN, USA)], 20 μL biotinylated antibody, and 
25 μL sample (or calibrator), which was followed by a 47 cadances 
incubation (1 cadance = 45 s). After washing, 100 μL of streptavidin-
conjugated β-galactosidase (Quanterix) was added, followed by a 
7-cadence incubation and a wash. Prior to reading, 25 μL Resorufin 
β-D-galactopyranoside (Quanterix) was added. The calibrator curve 
was constructed using the standard from the NF-light assay ELISA 
(NF-light®, UmanDiagnostics).
All measurements (ELISA, ECL assay, Simoa) were performed by 
board-certified laboratory technicians, who were masked to clinical 
data using one batch of reagents.
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Ethics statement
Written informed consent was obtained from all patients, and the 
study was approved by the Common Institutional Review Board of 
the Cantons of Basel.
Analytical and statistical analysis
Samples below the lowest calibrator reaching acceptance criteria 
[calibrator: accuracy: 80%–120%, coefficients of variation (CVs) of 
duplicate determination  ≤  20%] were assigned the concentration of 
the lowest calibrator reaching these criteria [9]. We used the con-
centration of the lowest calibrator fulfilling these acceptance cri-
teria as an estimate of the “analytical sensitivity” of each platform 
rather than the “limit of detection” that is often incorrectly used to 
describe assay “sensitivity”. The lower limit of quantification was 
not formally assessed for each of the platforms in this comparison 
study [10]. Samples above the highest calibrator (10,000 pg/mL) were 
assigned a concentration of 10,000 pg/mL. Repeatability (within-run 
precision) and intermediate precision (between-run precision) were 
calculated according to [11]. Intra-assay CVs were assessed between 
the concentrations of duplicates of the measured samples. All meas-
urements on the Meso Scale Diagnostics (MSD) and Simoa platforms 
were done in duplicates; the ELISA measurements were performed 
in single measurements, since based on large previous experience, 
intermediate precision and repeatability for the ELISA are below 20% 
and 10%, respectively.
Data are described by median and IQR if not stated other-
wise. NfL levels were compared between MS and each of the other 
groups (low, medium, high) by the Mann-Whitney test. Spearman 
correlation coefficients were calculated between NfL levels in CSF 
and serum and between the different platforms. All analyses were 
performed using GraphPad Prism 6.00 for Windows [GraphPad 
software, La Jolla, CA, USA (www.graphpad.com)] and IBM SPSS 
Statistics, version 22.
Results
Sensitivity of ELISA, ECL assay, and Simoa
Analytical sensitivity was 0.62 pg/mL for Simoa,  15.6 pg/
mL for the ECL assay, and 78.0 pg/mL for the ELISA. All 
CSF samples in all assays had concentrations above these 
levels. Eighteen of 33 (54.5%) serum measurements and 
20 of 33 (60.6%) were below sensitivity in the ELISA and 
ECL assay, respectively (Table 1). Of note, several ELISA 
serum measurements showed very high NfL concentra-
tions also in low and medium (low: 1/7 with very high 
NfL concentration, measured concentration: 3201 pg/mL; 
medium: 4/8, measured concentrations: 199, 219, 517, and 
1209 pg/mL). These five samples were all below analytical 
sensitivity when measured by the ECL assay and had low 
concentration with Simoa (range 7–18 pg/mL).
Intermediate precision, repeatability, and 
sample CVs for the ECL assay and Simoa
All samples were measured on the same day. Based on 
results from the previous 15 runs performed on separate 
days, intermediate precision/repeatability were 6.6%/3.6% 
(sample with mean concentration 72.8 pg/mL), 8.8%/6.4% 
(52.3 pg/mL) and 14.8%/9.2% (9.1 pg/mL), respectively, for 
the ECL assay. All sample CVs of duplicate measurements 
were below 10.8%.
Since the protocol for the Simoa assay is still under 
development, mainly due to planned upgrades of the 
platform, no complete formal validation has been per-
formed. Based on results from the previous 13 runs using 
the current protocol, intermediate precision/repeatability 
was 17.0%/6.6%, respectively (sample with mean concen-
tration of 64 pg/mL). All sample CVs of duplicate measure-
ments were below 12.5%.
Correlations between CSF and serum NfL
Correlations between paired CSF and serum samples were 
strongest for Simoa (r = 0.88, p < 0.001, Figure 1C) and the 
ECL assay (r = 0.78, p < 0.001, Figure 1B). This was less clear 
for the ELISA measurements (r = 0.38, p = 0.030, Figure 1A) 
(Table 1).
Correlations between ELISA, MSD and Simoa 
measurements
CSF
CSF NfL measurements on the three different platforms 
were highly correlated (ELISA-ECL assay: r = 1.0, p < 0.001, 
Figure 1D; ELISA-Simoa: r = 1.0, p < 0.001, Figure 1E; and 
ECL assay-Simoa: r = 1.0, p < 0.001, Figure 1F).
Serum
For serum measurements, NfL levels were highly corre-
lated between the ECL assay and Simoa (r = 0.86, p < 0.001, 
Figure 1I), whereas this relation was less strong for ELISA-
ECL assay (r = 0.41, p = 0.018, Figure 1G) and ELISA-Simoa 
(r = 0.43, p = 0.013, Figure 1H).
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Table 1: Results of CSF and serum NfL measurements in ELISA, ECL assay and Simoa.
  ELISA   ECL assay   Simoa
CSF (n = 33)
 Sensitivity   78.0 pg/mL   15.6 pg/mL   0.62 pg/mL
 NfL, pg/mL   1074 (426.0–3051.5)   965 (345–2727)   1649 (558.5–4997.5)
  N below sensitivity   0   0   0
  Low (n = 7)   317.0   272.0   475.0
  Medium (n = 8)   715.5   631.5   1009.5
  High (n = 9)   5611.0   5333.0   7854.0
  MS (n = 9)   2112.0   1834.0   3600.0
   Pair-wise 
comparison with MS
  Low: p=0.005
Med.: p = 0.074
High: p = 0.063
  Low: p=0.002
Med.: p=0.046
High: p=0.050
  Low: p=0.005
Med.: p = 0.059
High: p = 0.063
Serum (n = 33)
 NfL, pg/mL   78.0 (78.0–252.0)   15.6 (15.6–62.5)  22.0 (12.5–54.5)
  N below sensitivity   18 (54.5)   20 (60.6)   0 (0)
  Low   78.0a   15.6b   8.0
  Medium   138.0a   15.6b   16.5
  High   233.0   88.0   103.0
  MS   78.0a   15.6b   25.0
   Pair-wise 
comparison with MS
  Low: p = 0.837
Med.: p = 0.606
High: p = 0.040
  Low: p = 0.142
Med.: p = 0.074
High: p<0.001
  Low: p = 0.001
Med.: p = 0.074
High: p=0.003
CSF/serum correlations
 Spearman R and p   0.38, 0.030   0.78, <0.001   0.88, <0.001
CSF: Spearman R and p for correlation between ELISA, ECL assay and Simoa
 ELISA   –    
 ECL assay   1.0,  < 0.001   –  
 Simoa   1.0,  < 0.001   1.0,  < 0.001   –
Serum: Spearman R and p for correlation between ELISA, ECL assay and Simoa
 ELISA   –    
 ECL assay   0.41, 0.018   –  
 Simoa   0.43, 0.013   0.86,  < 0.001   –
aBelow lowest calibrator (78.0 pg/mL): low: 6/7 samples (1/7 measured concentration 3201 pg/mL); medium: 4/8 (4/8: 199 pg/mL,  
219 pg/mL, 517 pg/mL, and 1209 pg/mL); MS: 7/9 (2/9: 5595 pg/mL and 1891 pg/mL). bBelow lowest calibrator (15.6 pg/mL): low: 7/7; 
medium: 8/8; MS: 5/9. CSF, cerebrospinal fluid; ECL, electrochemiluminescence; MS, multiple sclerosis; NfL, neurofilament light chain.
Comparison between MS and low, medium, 
and high
CSF
MS patients had CSF NfL levels above low in all three 
platforms (ELISA: p = 0.005, ECL assay: p = 0.002, Simoa: 
p = 0.005). The difference between MS and medium or high 
only reached significance for the ECL assay (p = 0.046 and 
p = 0.050, respectively, Table 1).
Serum
Interestingly, the increase in serum NfL in MS vs. low only 
reached significance in Simoa (p = 0.001, Table 1). MS had 
significantly lower serum NfL than high in all three assays 
(ELISA: p = 0.04, ECL assay: p < 0.001, Simoa: p = 0.003).
Discussion
We found the Simoa platform to be 126- and 25-fold more 
sensitive than ELISA and the ECL assay, respectively, to 
quantify NfL. CSF and serum NfL measurements were 
highly correlated in the ECL assay and Simoa measure-
ments, whereas this relationship was weaker with ELISA. 
The correlation coefficients for CSF NfL measurements 
between the different platforms were 1.0. Conversely, 
only the serum NfL results from the ECL assay and Simoa 
showed a similar high relationship.
The Simoa technology relies on single-molecule 
arrays and the simultaneous counting of singulated 
capture microbeads [6, 7]. In contrast to analog immu-
noassays where the enzyme-substrate reaction is 
conducted in relatively large reaction volumes (50–
100 μL), Simoa restricts the diffusion of the fluorescent 
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Figure 1: CSF and serum NfL correlation in different assays (A–C), associations between NfL measurements on different platforms in CSF 
(D–F) and serum (G–I).
Correlations between paired CSF and serum samples were strongest for Simoa (r = 0.88, p < 0.001, Figure 1C), and the ECL assay (r = 0.78, 
p < 0.001, Figure 1B). This was less clear for the ELISA measurements (r = 0.38, p = 0.030, Figure 1A). CSF NfL measurements on the three 
different platforms were highly correlated: ELISA-ECL assay: r = 1.0, p < 0.001, Figure 1D; ELISA-Simoa: r = 1.0, p < 0.001, Figure 1E; and ECL 
assay-Simoa: r = 1.0, p < 0.001, Figure 1F. For serum measurements, NfL levels were highly correlated between ECL assay and Simoa (r = 0.86, 
p < 0.001, Figure 1I), whereas this relation was weaker for ELISA-ECL assay (r = 0.41, p = 0.018, Figure 1G) and ELISA-Simoa (r = 0.43, p = 0.013, 
Figure 1H).
molecules by femtoliter-sized wells that can be counted 
with a camera simultaneously in thousands of micro-
wells. The counting of active and inactive wells consti-
tutes a digital signal corresponding to the presence or 
absence of single enzyme molecules. This gain in sen-
sitivity permits the use of low quantities of the labe-
ling reagent, which lowers nonspecific interactions 
and increases signal-background ratios [7]. Indeed, we 
found the Simoa platform to be more than 100-fold more 
sensitive (0.62  pg/mL) than ELISA (78.0 pg/mL), and 
importantly, also 25-fold more sensitive than our previ-
ously described and validated ECL assay (15.6 pg/mL) 
[5]. For any potential future clinical application, it is of 
utmost importance to note that all serum samples were 
well in the measurable range of the Simoa NfL assay, 
with the lowest serum sample displaying a concentra-
tion of 2.0 pg/mL, 3.2-fold above the sensitivity of the 
assay. In contrast, more than 50% of the samples were 
not reliably quantifiable by the ECL assay and ELISA in 
our study.
Brain proteins access the blood flow either via CSF 
drainage in the venous blood or by diffusion through 
the blood-brain barrier. We have previously shown asso-
ciations between CSF and serum in ALS, Alzheimer’s 
disease, GBS and healthy controls [5, 12], which is in line 
with the present results. Indeed, CSF and serum meas-
urements were highly correlated with the ECL assay 
(r = 0.78, p < 0.001, Figure 1B) and Simoa (r = 0.88, p < 0.001, 
Figure  1C), but less so with ELISA (r = 0.38, p = 0.030, 
Figure  1A). We postulate that lower sensitivity together 
with unexpected high serum NfL measurements in some of 
the serum samples, caused by matrix effects like the pres-
ence of heterophilic antibodies, contributed to this smaller 
correlation between CSF and serum ELISA measurements 
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(see footnote Table 1) [13]. Heterophilic antibodies are also 
likely the cause for the apparently higher rate of measure-
ments below sensitivity with the ECL assay compared with 
the ELISA, which does not contain a blocker for this type 
of interference.
NfL measurements in CSF were perfectly correlated 
between the three platforms (Figure 1D–F). Of note, absolute 
CSF NfL levels tended to be higher with Simoa (1649 pg/mL), 
whereas concentrations measured by ELISA (1074 pg/mL) 
and the ECL assay (965 pg/mL) were more similar. This is an 
important observation and points to the need for standardi-
zation of calibrators and further work to allow direct com-
parability of concentrations between different platforms, 
centres, and studies. Also, despite the fact that our results 
seem to be, to some extent, expected (as all three platforms 
used the same mABs), several examples from the peer-
reviewed literature clearly show the difficulty of reproduc-
ing findings even with identical reagents and platforms [14, 
15]. These examples clearly point to the importance of thor-
ough biomarker validation, including longitudinal cohort 
studies, before implementing biomarkers for research, clini-
cal trials, or routine use in clinical practice [16].
Correlations between ELISA serum measurements 
and ECL assay or Simoa were visible and significant, but 
limited likely by the ELISA’s shortcomings described above 
(Figure 1G–H). Serum measurements between ECL assay 
and Simoa were highly associated (Figure 1I), with the ECL 
assay’s limitation that it cannot quantify concentrations 
below 15.6  pg/mL (20 of 33 samples). Our data confirm 
that serum NfL can be reproducibly measured on different 
sufficiently sensitive assay platforms and support the use 
of NfL measurements as a biomarker of neuronal damage 
also in the blood compartment.
We attempted to investigate CSF and serum NfL levels 
in MS vs. the preselected defined range samples (low, 
medium, high). We saw significantly higher CSF NfL levels 
in MS vs. low for all three platforms. Conversely, serum 
NfL in MS was only significantly higher than low for the 
Simoa measurements, whereas neither ELISA nor the ECL 
assay allowed quantification of any samples from the low 
or medium category. With the ECL assay, it was possible to 
quantify five of nine MS samples vs. zero with the ELISA 
(Table 1).
In conclusion, our results support the feasibility of 
quantifying NfL in CSF and serum samples as a measure 
of axonal injury. The highly sensitive Simoa technology 
especially deserves further studies in large and well-
characterized longitudinal patient cohorts. Large studies 
including longitudinal sampling will also be needed 
to clarify whether serum NfL can be used in the future 
to measure disease severity and determine prognosis 
or/and response to treatment interventions in various 
 neurological diseases.
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